<DOC>
	<DOCNO>NCT00110994</DOCNO>
	<brief_summary>This randomize , double blind , placebo control , multicenter , phase II study compare anti-tumor activity measure progression-free survival ( PFS ) tolerability Sorafenib combination Dacarbazine ( DTIC ) versus DTIC combination placebo subject unresectable Stage III Stage IV melanoma receive prior cytotoxic chemotherapy . A total approximately 98 subject randomize receive DTIC + Sorafenib DTIC + Placebo .</brief_summary>
	<brief_title>Treatment Subjects With Unresectable Stage III Stage IV Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients life expectancy least 12 week Patients histologically cytologically confirm unresectable ( Stage III ) metastatic ( Stage IV ) melanoma Patients ECOG PS 0 , 1 Measurable disease define least one lesion accurately serially measure per modify RECIST criterion Primary ocular mucosal melanoma Previous concurrent cancer distinct primary site histology cancer evaluate study except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta [ Noninvasive papillary carcinoma ] , Tis [ Carcinoma situ : `` flat tumor '' ] &amp; T1 [ Tumor invade subepithelial connective tissue ] ) cancer curatively treat &lt; 3 year prior study entry History cardiac disease Known history human immunodeficiency virus ( HIV ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>